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ABSTRACT  
Background: Deprescribing, the process of reducing or discontinuing unnecessary or harmful medicines is an 
essential part of clinical practice.  
Objective: To evaluate the efficacy of interventions designed to deprescribe opioid analgesics for pain relief in 
patients with chronic non-cancer pain. 
Methods: We searched electronic databases including clinical trial registries from database inception to 13th 
January 2020 without restrictions, and conducted citation tracking. Our systematic review included randomised 
controlled trials (RCTs) evaluating interventions reducing the prescription, or use, of opioid analgesics in 
patients with chronic pain versus control. Inventions could be aimed at the patient, clinician or both. We 
excluded trials enrolling patients with cancer or illicit drug use. Two authors independently screened and 
extracted data. Outcome follow-up timepoints were short (≤ 3 months), intermediate (> 3 but < 12 months) or 
long (≥ 12 months) term. Primary outcome was the reduction in opioid dose (morphine milligram equivalent 
(MME) mg/day). Methodological quality was assessed using the Cochrane Risk of Bias Tool. 
Results: We included 10 patient-focused RCT interventions (n = 835; median = 37 participants) and 2 testing 
clinician-focused interventions (n = 291 clinicians); none at low risk of bias. Patient-focused interventions did 
not reduce opioid dose at intermediate-term (e.g. dose reduction protocol, Mean Difference (MD) -19.9 MME, 
95%CI -107.5 to 67.7), nor increased the number of participants who ceased their dose, nor increased the risk of 
serious adverse events or adverse events. One clinician intervention of education plus decision tools versus 
decision tools alone reduced the number of opioid prescriptions (Risk Difference (RD) -0.1, 95%CI -0.2 to -0.1), 
dose (MD -5.3 MME, 95%CI -6.2 to -4.5) and use (RD -0.1, 95%CI -0.1 to -0.0) at long-term.  
Limitations: Study heterogeneity prevented meta-analysis. 
Conclusion: The small number of studies and heterogeneity prevented firm conclusions to recommend any one 
opioid analgesic deprescribing strategy in patients with chronic pain. 









Deprescribing is the process of reducing or discontinuing unnecessary or harmful medicines[1]. To address the 
‘opioid epidemic’, clinical practice guidelines now discourage the initial prescription of opioid analgesics for 
chronic non-cancer pain[2] and strategies such as the introduction of Prescription Drug Monitoring Programs 
may reduce opioid prescribing[3, 4]. The management of people currently taking opioid analgesics requiring 
deprescribing can be a daunting task. There is no consensus on how to guide clinicians to deprescribe opioid 
analgesics. However, the overall concept of dose tapering involves the reduction of the dose slowly over time, 
such as 10% reduction per week, or longer if patients have been using their opioid analgesic for a prolonged 
time while monitoring side effects[5, 6]. Qualitative research has identified several obstacles that make 
deprescribing difficult including; clinician uncertainty around applying evidence-based medicine[7], and 
patient’s fear of pain, withdrawal symptoms, the perceived lack of effectiveness of many non-opioid therapies 
and access of non-opioid options[8, 9]. 
 
Clinicians need to know which opioid dose reduction methods are most effective and safe for deprescribing 
opioid analgesics in patients with chronic pain[10]. Previous reviews of randomised trials assessing opioid 
analgesic deprescribing strategies in chronic pain have been inconclusive due to the limited number of 
studies[11] or focused on long-term opioid therapy (opioid use greater than one year)[12]. Since their 
publication, new randomised trials have emerged. Therefore, we aimed to review the current evidence of the 
efficacy of interventions designed to reduce/cease the prescription of, or the use of opioid analgesics in patients 
with chronic non-cancer pain. 
 
2. METHODS   
2.1 Data sources 
This registered systematic review (PROSPERO: CRD42017068422) was conducted according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines[13]. We searched PubMed 
(Legacy), MEDLINE, EMBASE, PsycINFO, Web of Science (Core Collection), Cochrane Central Register of 
Controlled Trials, International Pharmaceutical Abstracts, ClinicalTrials.gov, and the World Health 
Organization International Clinical Trials Registry Platform from database inception to 13th January 2020 with 
no language or publication date restrictions (SM). The database search strategy is presented in Appendix 1. We 
also conducted manual searching of reference list of included studies, and backward and forward citation 
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tracking of included papers using Scopus. We contacted authors by email with one follow up contact if relevant 
data were missing to determine eligibility (n = 11 studies).  
 
2.2 Study selection 
Two review authors from a panel (SM plus GF or MH) independently screened titles and the abstracts and full text 
of potentially eligible studies, and independently appraised eligibility. Disagreements were resolved by 
discussion first, then arbitration by a third author (CM). We included randomised controlled trials that evaluated 
an intervention to reduce or cease the prescription or use of prescription (non-illicit) opioids in adult (18 years) 
patients with chronic pain (i.e. three months’ duration or longer) in a clinical setting compared to usual care (i.e. 
no intervention) or active control. The invention could be aimed at the patient, clinician or both. Interventions 
that were patient-focused aimed at reducing a patient’s opioid dose, whereas clinician-focused interventions 
aimed at changing the clinician’s behaviour. We excluded trials that exclusively enrolled patients with cancer, 
illicit drug users or women who were pregnant. We also excluded studies where opioid analgesics were not used 
for pain management. 
  
2.3 Outcomes 
The primary outcome was the mean reduction of daily dose (in morphine milligram equivalents) of opioid 
analgesic medication(s). Secondary outcomes were the reduction of opioid analgesic prescriptions, the 
proportion of participants who ceased or reduced their opioid use, the number of serious adverse events and 
adverse events reported, and the mean change in pain intensity, disability and quality of life scores. 
 
2.4 Data extraction and management 
Two review authors from a panel (SM plus GF or MH) independently extracted data using piloted forms. 
Disagreements were resolved by discussion first, then arbitration by a third author (CM). Data extraction 
included bibliometric data (e.g. language, funding sources); study characteristics (e.g. setting, sample size); 
participants (e.g. age, gender, diagnosis, symptom duration); interventions and controls (type (i.e. medicine or 
therapy), dose, duration, mode of delivery); outcome data (e.g. proportion of participants who reduced or ceased 
their medication, serious adverse events including descriptors); and data completeness (i.e. percentage of 
missing data, how missing data were handled). Opioid analgesic medicines were defined as medicines listed as 
N02 according to the Anatomical Therapeutic Chemical (ATC) classification system[14] and were converted to 
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morphine milligram equivalent (MME)[2] dose if necessary to standardise for comparison. Follow-up time 
points of outcomes in individual studies were categorised as short (≤ 3 months), intermediate (> 3 but < 12 
months) or long (≥ 12 months) term. If multiple time points fell within the same period, we used the time-point 
closest to seven weeks, six months and 12 months.  
 
2.5 Risk of bias assessment 
Methodological quality was independently assessed by two authors (the same authors who extracted the data on 
that study) using the Cochrane Risk of Bias Tool[15] (Appendix 2). Disagreements were resolved by discussion 
first, then arbitration by a third author (CM). A study was considered to have a low risk of bias if the study was 
scored low in six or more domains with no high risk of bias scores[15]. 
 
2.6 Data synthesis 
The flow of studies was summarised in a study flow diagram following the PRISMA statement[13]. Study 
characteristics were reported descriptively. A narrative synthesis was used to present the results as clinical and 
statistical heterogeneity (I2 > 50%) prevented conducting a meta-analysis. Continuous outcomes are presented as 
mean differences between the intervention and control groups, and dichotomous outcomes are presented as 
absolute risk differences between the intervention and control groups. Heterogeneity prevented the assessment 
of the overall quality of evidence using a Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) approach[16]. We were also unable to perform the pre-planned sensitivity analysis (i.e. 
explain potential sources of heterogeneity and differences in risk of bias) and subgroup (i.e. chronic low back 
pain population) analyses due to the low number of studies.  
 
3. RESULTS  
The search retrieved 37,406 records, of which 12 trials were included in this review plus ten ongoing clinical 
trials (NCT02737826, NCT03521960; NCT03743402, NCT03889418, NCT03916276, NCT03950791, 
NCT04013529, NCT04097743, NCT04184362, ISRCTN49470934) (Appendix 3). All studies were published 
from 2010 onwards, were published in English and were all conducted in the United States of America except 




3.1 Study characteristics 
3.1.1 Patient-focused interventions 
A total of 835 adult participants with chronic non-cancer pain were randomised with a mean age of 48.0 years 
(Standard Deviation (SD) 16.9). Most trials were of small size (median = 37 participants with chronic pain 
range 12 to 411) (Table 1). There were 10 studies of patient-focused interventions[17-26] including: 
 Dose reduction protocols[18, 23, 24]. Two studies specifying dose reduction targets as part of the 
protocol such as starting with a 10% reduction of daily dose every week[18, 24]. One study initiated 
dose reduction by sending a letter to both patients and their community-based providers upon 
emergency department discharge[23]. 
 Opioid replacement with buprenorphine[19, 25] (e.g. gradual tapering versus steady dosing[19], 
tapering versus switching to morphine sulfate or oxycodone hydrochloride[25]) or varenicline[21] 
(titration up 1 mg twice daily versus placebo). 
 Non-pharmacological therapies of mindfulness (versus active control of support group sessions)[20], 
Therapeutic Interactive Voice Response program (versus usual care)[22], meditation and cognitive 
behavioural therapy (versus usual care)[26], and electroacupuncture (versus sham)[17]. 
The most frequent comparator was usual care or no change in treatment[18, 22-24, 26].  
 
3.1.1 Clinician-focused interventions 
There were two clinician-focused interventions where the deprescribing intervention targeted changing clinician 
behaviour[27, 28] (Table 1) (n = 291 clinicians, 985 adults with chronic pain). Clinician-focused deprescribing 
interventions were an education-based multicomponent intervention in primary care consisting of training 
sessions plus decision tools to improve guideline adherence and decrease opioid misuse risk (e.g. early 
prescription refills) versus decision tools[27]; and online education of patient simulation plus case-based 
learning for safer prescribing to reduce prescribing behaviour (e.g. early prescription refills) versus existing 
online education[28]. 
 
3.2 Risk of bias  
No study had an overall low risk of bias (Figure 1). Blinding was the most frequent domain not met; 66% of 
studies did not have participant blinding, 91% of studies did not blind intervention providers, and 50% of 
studies did not blind outcome assessors. Two studies were scored ‘high’ risk of bias due to high dropout rates 
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during follow-up [18, 20]. Industry sponsorship was scored within ‘other bias’. We identified one industry-
funded study[25], and two studies where the role of industry funding was unclear[19, 28]. 
 
3.3 Outcomes 
3.3.1 Morphine equivalent daily dose reduction 
The reduction in daily morphine equivalent dose due to deprescribing interventions was reported by three 
patient-focused intervention studies of dose reduction protocols[18, 24], non-pharmacological therapies[17] and 
one clinician-focused intervention of multicomponent training sessions and decision tools versus decision tools 
alone[27] (Figure 2). In the patient-focused intervention studies, the mean baseline opioid dose was relatively 
high at 154.9 MME/day (n = 8 studies of 340 people with chronic pain, mean range 66.2 to 275.5 MME/day). 
Considerable statistical (I2 = 92%) and clinical heterogeneity prevented pooling data. Only one of the four 
studies showed a significant difference in the daily dose between groups using a dose tapering protocol[18] 
(Mean Difference -27.9 MME/day, 95%CI -41.1 to -14.7) (Figure 2), however, this study had a number of 
dropouts. One clinician-focused study (n = 985 participants with 53 physicians) did significantly reduce daily 
opioid dose compared to decision tools alone at long-term follow-up[27] (Mean Difference -5.3 MME/day, 
95%CI -6.2 to -4.5). 
 
3.3.2 Reduction of opioid prescriptions 
The number of opioid analgesic prescriptions reduced by deprescribing interventions was reported in four 
studies; three patient-focused interventions [19, 23, 24] and one clinician-focused intervention[27] (Figure 3). 
Clinical heterogeneity prevented pooling of two patient-focused intervention studies at immediate-term (n = 47), 
however, one study showed a borderline significant effect of dose reduction protocol[24] (Risk Difference -0.3, 
95%CI -0.6 to -0.0; 77.8% reduction of prescriptions in the intervention group versus 47.1% in the control 
group). At long-term follow-up, one patient-focused intervention of a dose reduction protocol (n = 406)[23] and 
one clinician-focused study[27] did have a significant risk difference favouring the deprescribing interventions 
(Risk Difference -0.1, 95%CI -0.1 to -0.0; 10% reduction of prescriptions in the intervention group versus 1.9% 
in the control group; and Risk Difference -0.1, 95%CI -0.2 to -0.0; 47.1% reduction of prescriptions in the 




3.3.3 Number of participants who ceased using their opioid analgesic prescription  
Five studies reported the number of participants who ceased using their opioid analgesics due to deprescribing 
interventions; four patient-focused intervention studies[19, 21, 22, 24] and one clinician-focused 
intervention[27] (Figure 3). None of the four patient-focused deprescribing interventions significantly reduced 
the proportion of patients with chronic pain who ceased their opioid analgesic compared to controls (Figure 3). 
One clinician-focused study[27] nearly showed statistical significance at long-term (Risk Difference -0.1, 
95%CI -0.1 to 0.0; 21.3% ceased in the intervention group versus 16.8% in the control group). 
 
3.3.4 Number of participants who reduced the dose of their opioid analgesic prescription 
The proportion of participants who were able to reduce their opioid analgesic use was reported by six studies; 
five patient-focused interventions[17, 19, 21, 24, 25] and one clinician-focus intervention[27] (Figure 3). 
Clinical heterogeneity prevented pooling the patient-focused intervention studies. There were no significant 
effects of deprescribing interventions at short-term (n = 170) or at intermediate-term (n = 47) except a 
moderately large risk difference of borderline statistical significance favouring one patient-focused intervention 
of a dose reduction protocol[24] (Risk Difference -0.3, 95%CI -0.6 to 0.0; 72.2% reduced their opioid use in the 
intervention group versus 41.2% in the control group). One clinician-focused intervention did have a significant 
risk difference favouring the intervention[27] in reducing a patient’s daily use at long-term (Risk Difference -
0.1, 95%CI -0.1 to -0.0). Reduction was defined as 10% reduction in opioid dose within 30 days. 
 
3.3.5 Adverse events 
Serious adverse events were reported in four studies of patient-focused interventions[17, 21, 24, 25]. Serious 
adverse events were infrequent (at short-term, one event in 93 participants in the intervention group, and zero 
events in 77 participants in the control group. At intermediate-term one event in 18 participants in the 
intervention group, and zero events in 17 participants in the control group). There was no risk difference 
between groups for serious adverse events (Figure 4). Serious adverse events were chest pain and dyspnoea[25], 
and an allergic reaction[24]. Adverse events were reported in three studies of patient-focused interventions[17, 
24, 25]. There was no risk difference between groups for the number of participants reporting adverse events at 
short-term (Risk Difference 0.1, 95%CI -0.1 to 0.3) or intermediate-term (Risk Difference 0.0, 95%CI -0.1 to 
0.1) [24, 25] (Figure 4). Of the ten patient focused interventions, there were 11 participants who withdrew due 
to adverse events (of which nine withdrawals were due to worsening symptoms/lack of efficacy)[17, 19, 25]. 
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Five studies did not have any adverse event withdrawals [21-24,26], while two studies did not provide sufficient 
detail to determine if the reasons of the study withdrawal were adverse event related [18, 20]. 
 
3.3.6 Pain, disability and quality of life 
Pain outcomes were reported in seven studies of patient-focused interventions [17, 18, 20, 21, 22, 24, 26] 
(Online Resource Appendix 4). Considerable statistical heterogeneity prevented pooling at short-term and 
intermediate-term (I2 = 100%, I2 = 95% respectively). Overall, two studies reported greater reduction in pain in 
the intervention group compared to controls[20, 24].  
 
Disability outcomes were reported in six studies of patient-focused interventions[17, 18, 20, 22, 24, 26] (Online 
Resource Appendix 4). Statistical heterogeneity prevented pooling at short-term and intermediate-term (I2 = 
99%, I2 = 57% respectively). Overall, two studies demonstrated a greater reduction in disability compared to 
controls[20, 24].  
 
Quality of life outcomes were reported in three studies of patient-focused interventions[17, 18, 22] (Online 
Resource Appendix 4). Overall, one study had a small effect on quality of life mental and physical composite 
scores[17]. 
 
4. DISCUSSION  
Our review updated the current body of evidence and found twelve eligible randomised controlled trials of which 
none were considered to have overall low risk of bias, and statistical and clinical heterogeneity prevented firm 
recommendations to support any opioid analgesic deprescribing strategy for chronic pain. Patient-focused 
deprescribing interventions were of dose reduction protocols, opioid replacement or a range of non-
pharmacotherapies such as mindfulness. One deprescribing intervention (a dose reduction protocol) reduced the 
daily opioid dose at short-term. However, the other dose reduction protocol did not reduce the daily opioid dose 
at intermediate-term. Overall, patient-focused deprescribing interventions did not reduce the number of 
participants who ceased their opioid medicine or increased the risk of serious adverse events or adverse events. 
Clinician-focused deprescribing interventions that targeted changing clinician behaviour were education-based 
and showed a reduction in the daily opioid dose prescribed, opioid use and the number of prescriptions issued at 
long-term.  
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The strength of our review includes extending the previous small body of literature by incorporating five new 
randomised trials [18, 20, 23, 27, 28] plus identifying ten registered, ongoing randomised trials potentially 
eligible for inclusion in future reviews. Homogeneity was noted as most studies were published from the USA. 
The quality of the evidence may increase over time especially if new eligible studies are conducted with 
enhanced methodological rigour. The addition of new trials will also provide a greater evidence base to  
generalise the results across different types of chronic pain conditions and healthcare systems. An additional 
strength is that we included all studies regardless of publication language and length of opioid use when 
prescribed for the management of pain. However, clinical and statistical heterogeneity limited our findings of the 
review due to the range of deprescribing interventions across the small pool of eligible randomised trials and 
prevented any subgroup analyses of assessing deprescribing interventions in patients with chronic low back pain. 
 
Previous reviews assessing deprescribing interventions to cease opioid analgesics in chronic pain were also 
unable to draw definite conclusions due to heterogeneity[11], and low methodological quality[12, 29]. Two of 
these previous reviews[11, 29] were small (i.e. including five randomised trials) while the other review was 
larger by including both controlled and uncontrolled observational studies as well as randomised controlled trials 
of patients on long-term opioid therapy (n = 67 studies). Our review is the first review to consider if industry 
support potentially influenced study findings by considering industry funding in the risk of bias assessment. We 
identified two studies where the role of industry funding was unclear[19, 28]. Similarly to the review by Frank et 
al[12], we noted that randomised trials often were inadequately powered due to the small number of participants 
and some studies having high dropout rates to the point of study discontinuation (e.g. Kurita 2018). However, we 
did not assess sample size within the risk of bias assessment like the review by Eccleston et al who rated studies 
as high risk of bias if there were fewer than 50 participants per treatment arm. 
 
Our review highlights the urgent need for more research to identify evidence-based methods to decrease the use 
and prescription of opioid analgesics in chronic non-cancer pain. At present, the lack of evidence to support any 
particular deprescribing intervention creates uncertainty for clinicians on how they might best manage their 
patients with chronic pain taking opioid analgesics. Meanwhile, clinicians may reflect on individual studies for 
empirical evidence to guide their deprescribing in patients with chronic pain. For example, in two studies that 
reported positive conclusions, behavioural approaches were incorporated into the deprescribing process[20, 24]. 
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However, patients may find access to behavioural programs via pain management programs costly or less 
accessibile; and sourcing behavioural treatments in another setting may be worthwhile. 
 
Future research is needed to establish effective strategies for reducing the initial prescription of opioid 
analgesics, which in turn may prevent the potential need for future opioid cessation strategies. We found 
clinician-focused interventions could change clinician’s prescribing behaviour, leading to the reduction of 
issuing early prescription refills. Future clinician-focused educational strategies may also consider methods to 
delay or reduce the number of initial prescription of opioids to patients with chronic pain. Opioid stewardship 
programs such as coordinated programs that promote appropriate use of opioid medication, may provide 
strategies to reduce long-term opioid use and to reduce the initial prescription of opioid analgesics. Research into 
reducing opioid use in patients with chronic pain could evaluate strategies of dose reduction protocols that 
include a patient support component such as pain management education. This strategy is similar to the small 35-
participant pilot study by Sullivan et al. However, the effects of this strategy should be evaluated in a larger 
sample of randomised patients with chronic pain before making any strong clinical recommendations. 
Additionally, we did not find a larger scale version of the Sullivan et al study as a registered clinical trial. Future 
research into strategies to reduce the unnecessary prescription of opioids may further investigate clinician-
focused deprescribing interventions. 
 
5. CONCLUSION  
Currently, the small number of randomised trials, and clinical and statistical heterogeneity prevent any firm 
conclusions on the recommendation of any specific opioid analgesic deprescribing strategy for people with 
chronic pain. Overall, patient-focused deprescribing interventions frequently did not provide a greater effect in 
the intervention group compared to controls. However, one clinician-focused deprescribing intervention did 
change clinician prescribing behaviour at long-term and may be an implementable deprescribing strategy upon 
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Fig 1 Summary of risk of bias 
 
Each domain was scored as low risk of bias (+), unclear (?) or high (-) risk of bias.
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Fig 2 Daily morphine milligram equivalent dose reduction (mg/day) 
 
Abbreviations: IV = Inverse Variance; CI = Confidence Interval; S = Short-term follow-up; I = Intermediate-term 
follow-up; L = Long-term follow-up. 
 
Patient-focused interventions varied and included dose reduction protocols (Kurita 2018[18], Sullivan 2017[24]) 
and non-pharmacological interventions (Zheng 2018[17]). The clinician-focused study was of multicomponent 
training sessions and decision tools (Liebschutz 2017[27]). Other studies that reported dose reduction included 
Trudeau 2017[28] but reported as a categorical measure of reluctance prescribing opioids on a 1 to 5 Likert scale; 
individual group scores were unavailable in Zgierska 2016[26] and standard deviation unavailable in Blondell 




Fig 3 The effect of deprescribing interventions on the reduction of opioid prescriptions, and the number of 
participants ceasing and reducing their opioid analgesic use. 
 
Abbreviations: M-H = Mantel-Haenszel; CI = Confidence Interval; S = Short-term follow-up; I = Intermediate-
term follow-up; L = Long-term follow-up. 
 
Patient-focused interventions varied and included opioid replacement therapy with varenicline (Hooten 2015[21]) 
or buprenorphine (Blondell 2010[19], Webster 2016[25]); non-pharmacological interventions (Naylor 2010[22], 
Zheng 2018[17]); and dose reduction protocols (Sullivan 2017[24], Ringwalt 2015[23]). The clinician-focused 


























Fig 4 The risk difference of opioid analgesic deprescribing interventions on serious adverse events and adverse 
events 
 
Abbreviations: M-H = Mantel-Haenszel; CI = Confidence Interval; I = Intermediate-term follow-up; L = Long-
term follow-up. 
 
All studies were patient-focused interventions and included opioid replacement therapy with varenicline (Hooten 
2015[21]) or buprenorphine (Webster 2016[25]); a non-pharmacological intervention (Zheng 2018[17]); or dose 
reduction protocol (Sullivan 2017[24]).  Events represent the number of participants with one or more (serious) 
adverse events. One study reported adverse events per the number of electroacupuncture sessions rather than 
participants (86 events/496 sessions in the electroacupuncture group, 70 events/329 sessions in the sham 
electroacupuncture group; Risk Difference 0.4, 95%CI 0.1 to 0.7)[17].
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Study Study population Intervention Outcomes Conclusions 
Patient interventions  










All participants were admitted to hospital to stabilise opioid dose (4 
mg sublingual buprenorphine/naloxone tablet + 2mg dose every 2 
hours until withdrawal symptoms and signs controlled, ~24-48 
hours). At discharge participants were randomised (open label) to 
either: 
Opioid discontinuation protocol (gradual buprenorphine/naloxone 
tapering over 4 months (<16 mg/day), then discontinued for 2 
months. Participants could opt out of the tapering protocol and 
initiate steady dose schedule) 
OR 
Steady or regular buprenorphine/naloxone dosing (<16 mg/day 
for 6 months). Rescue medicine and requested to continue usual 








“Participants with chronic non-
cancer pain and coexistent opioid 
addiction were more likely to 
adhere to steady doses of 
buprenorphine for opioid 
replacement therapy than tapering 
doses of buprenorphine for opioid 
discontinuation therapy. None of 
the 6 participants in the tapering 
arm could successfully complete 
the 6-month protocol”. 
Garland et al 
2014[20] 
115 chronic non-
cancer, arthritis or 
fibromyalgia 
patients from 
primary and tertiary 
care clinics, USA 
Mindfulness-Oriented Recovery Enhancement (MORE) (8-
session group intervention of 8-12 individuals of 2 hours duration 
including mindfulness training, positive reappraisal training, raining 
in favouring pleasant events and positive affectivity. Homework 
included CD guided 15 minute mindfulness practice session) 
Or 
Active control (support group sessions) (8 weekly, 2-hour 
conventional support group sessions of 8-12 individuals with 
facilitator led discussion topics pertinent to chronic pain and long-
term opioid use, matched to MORE intervention themes). 
Pain, disability at 
short and 
intermediate-term. 
“MORE reduces pain severity and 
functional interference for up to 3 
months following treatment, and 
decreases sympathetic stress 
arousal, desire for opioids, and 
disordered opioid use at the end of 
treatment” 
Hooten et al 
2015[21] 
21 chronic non-
cancer patients of 
interdisciplinary 
pain program, USA 
Patients within interdisciplinary pain program were randomised to 
either:  
Varenicline (0.5 mg QD for 3 days, then 0.5 mg BID days 4 to 7, 
then 1 mg BID days 8 to 15). 
Or 
Placebo (identically appearing tablets). 
Number 
ceased/reduced, 
pain and SAE at 
short-term. 
The pilot study found “that opioid 
withdrawal scores tended to 
decrease over the course of opioid 
tapering in those receiving 
varenicline and increase in those 
receiving placebo. Varenicline was 
well-tolerated in this population, 
with no adverse drug effects 
(including nausea) observed and no 
effect on improvements in pain 
severity and depression.” 
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Kurita et al 
2018[18] 
35 chronic non-
cancer patients on a 
waiting list to a 
pain centre, Demark 
Taper off group (10% reduction of the daily opioid dose every 
week (or 2 weeks if necessary) until discontinuation of opioid 
treatment for up to 6 months). Clonidine use (25–150 µg/day) 
permitted to manage withdrawal. Managed by a multidisciplinary 
team). 
Or  
Control (maintained same treatment for next 6 months. Offered 
intervention on study completion). 
Dose reduction, 
pain, disability and 
quality of life at 
short-term. 
“The opioid tapering-off program 
was not successful due to the vast 
number of dropouts”. “However, 
improvements after opioid 
treatment stabilization were 
achieved and stable pain intensity 
in those tapered off may encourage 
the development of more refined 
programs.” 




pain (back pain, 
osteoarthritis, 
fibromyalgia) 
patients at a 
university medical 
centre, USA 
All participants completed group pain coping skills training of 90-
minute weekly sessions over 11 weeks. Then randomised to either: 
Therapeutic Interactive Voice Response (TIVR) program plus 
usual care (4 months access to TIVR, where participants interact 
with a computer through the telephone keypad that aims to maintain 
treatment gains following their pain coping skills training. TIVR 
has four components: 1) 21-item daily self-monitoring 
questionnaire about pain, medication etc; 2) didactic review of 
skills, a verbal review of the 8 pain management skills learnt during 
skills training; 3) guided behavioural rehearsal of pain coping skills, 
pre-recorded voice of a therapist guiding them through behavioural 
rehearsals from skills training; 4) a monthly therapist feedback 
message, a personalised recorded message from the therapist). 
Or  
Usual care (per participants usual sources, unmeasured) 
Dose reduction, 
number ceased, 
pain, disability and 
quality of life at 
intermediate-term. 
“We have previously demonstrated 
the efficacy of Therapeutic IVR to 
decrease pain and improve 
coping; this analysis demonstrates 
that the use of TIVR may also 
result in concurrent reductions in 
opioid analgesic and NSAID 
medications use.” 
Ringwalt et al 
2015[23] 
411 chronic non-
cancer patients  
from 13 Emergency 
Departments, USA 
 
Patients identified in electronic medical records with frequent (>10) 
visits to the emergency department over a 12 month period were 
randomised to either:  
Intervention (1) advice to the patient’s emergency department 
provider to advise the patient to visit a community-based primary 
care provider, pain clinic etc. on a supplied handout, and not to 
prescribe opioids; and 2) a letter sent to both patients and their 
community-based providers informing that a group of medical 
providers determined that they should no longer receive opioid pain 
medication). 
Or 





“Our study has demonstrated the 
positive effects of our intervention 
on repeat visits and opioid 
analgesics prescribed to a 
population of very frequent visitors 
to a set of electronically linked EDs 
who are characterized by 
CNCP”. 
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and tertiary clinics, 
USA 
Non-blinded randomisation to either: 
Opioid Taper Support intervention (10% reduction of original 
dose per week until 30% of original dose reached. Then, 10% 
reduction recalculated, then proceeded by 10% of this new dose per 
week. Plus 17 weekly 30-minute support sessions containing pain 
self-management, pain education, behavioural techniques, sleep 
education. Homework included workbook, CD with relaxation 
exercises. 
Or 









SAE, AE at 
intermediate-term. 
The pilot study showed “lower 
opioid doses and pain severity 
ratings were observed at 22 weeks 
in both groups. The groups did not 
differ significantly at 22 weeks in 
opioid dose or pain severity, but the 
taper support group improved 
significantly more in pain 
interference, pain self-efficacy, and 
perceived opioid problems” 
Webster et al 
2016[25] 
 
39 chronic pain 
patients in a clinic 
in USA 
Patients receiving around-the-clock µ-opioid agonist therapy 
(confirmed opioid dependent by naloxone challenge), continued 
their opioid therapy and randomised (cross-over study, double-
blind, double-dummy to either: 
Treatment AB (Treatment A of 2 doses of buccal buprenorphine. 
A subject’s original dose was reduced to 50%, then given 2 doses of 
either 300 or 450 µg of buprenorphine (determined by original 
dose) for 24 hours duration, then received their normal opioid 
therapy. After returning to clinic 7-14 days later, participants 
received Treatment B of 2 doses of active full µ-opioid agonist, 
morphine sulfate or oxycodone hydrochloride, for 24 hours).  
Or 
Treatment BA (Treatment B then Treatment A, as detailed above).  
Number patients 
reduced, SAE, AE 
at short-term. 
“Chronic pain patients treated with 
around-the-clock full µ-opioid 
agonist therapy can be switched to 
buccal buprenorphine (a partial µ -
opioid agonist) at approximately 
50% of the full µ -opioid agonist 
dose without an increased risk of 
opioid withdrawal or loss of pain 
control”. 
Zgierska et al 
2016[26] 
35 chronic low 
back pain patients 
from a University 
outpatient clinic, 
USA 
Mediation-CBT group plus usual care (2 hour sessions for 8 
weeks of mindfulness meditation & cognitive behavioural therapy. 
Plus, homework of 30 minute mindfulness practice, ≥ 6 days per 
week).   
Or 
Usual Care (for 8 weeks duration. Participants could receive the 
intervention on study completion). 
Dose reduction, 





The pilot study found that 
“meditation-CBT intervention 
reduced pain severity … in patients 
with opioid-treated CLBP”. “We 
did not find a statistically 
significant decrease in the use of 
opioid medications during this 
study”. 
Zheng et al 2018[17] 77 chronic 
musculoskeletal 




After a 5 week run-in period to stabilise all treatments, all patients 
received pain medication management (PMM) brochure in the 5th 
week. Participants were given individualised opioid medication 
reduction schedules and asked to reduce their dosage by 30% in 
week 8, 50% by week 11, and 75% to 100% by week 14, as long as 
their pain did not get worse). Then randomised to 10 week 





SAE, and AE at 
short and 
intermediate-term. 
There was “reduced opioid 
medication usage in the 
Short-term with no group 
difference either at the end of the 
treatment or the follow-up. 
Reduction of OM-related (opioid 
medications] adverse events and 
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Electoacupuncture (EA) (≥ 12 needles per session, consisting of 
four formula points and eight supplementary points chosen 
according to the adverse effects of opioid medications participants 
experienced that week. Sessions were twice a week for 4 weeks, 
then once a week for 2 weeks, then every 2 weeks for 4 weeks. 
Or 
Sham electoacupuncture (SEA); Sham electroacupuncture was 
simulated with a manufacturer-modified non-functioning stimulator 
to match a set of sham points. Same session schedule as EA group. 
pain and improvement of function 
and depression were similar”. 
Clinician interventions  
Liebschutz et al 
2017[27] 
53 primary care 
clinicians from 4 





Clinicians with patients receiving long-term opioid therapy with an 
active opioid prescription in the past 60 days were randomised to 
either:  
Multicomponent primary care-based intervention (TOPCARE) 
included 4 components; (1) Nurse care manager collected 
information e.g. pain, prepare prescriptions, opioid misuse risk; (2) 
web-based electronic registry to facilitate population management 
from electronic health record; (3) single 1-on-1 academic detailing 
session; and (4) orientation and access to electronic decision tools 
online platform. For 12 months duration; to improve guideline 
prescribing adherence and decrease misuse (e.g. reduce prescription 
of early refills). 
Or  
Control intervention (orientation and access to electronic decision 








“A multicomponent intervention 
improved guideline-concordant 
care but did not decrease early 
opioid refills”. 
Trudeau et al 
2017[28]  
238 primary care 
clinicians, USA 
Clinicians who provided treatment for chronic non-cancer pain 
patients in the last 90 days were randomised to either:  
Online education (Managing Addiction and Pain in Primary Care 
(MAP-PC) program, which is an immersive, standardised patient 
simulation–type, case based continuing education program about 
the management of chronic pain and addiction to reduce prescribing 
behaviour (e.g. early refills).  
Or  
Active control (existing online continuing education courses with 
text-based content). 





“Findings suggest online CE 
[continuing education] programs 
may positively impact PCPs’ 
knowledge, attitudes, and pain 
practice behaviors”. “Post hoc 
comparisons suggested that 
participants in the experimental 
condition were less likely to 
endorse use of opioid TRFs 
[tamper-resistant formulations] 
over time compared with the 
control”. 
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Ongoing studies     
Identifier Status Title  Outcomes 
reported 
 
NCT02741076 Active, not 
recruiting chronic 
low back pain 
patients 
Structured discontinuation vs continued therapy in suboptimal and 




NCT03521960 Recruiting patients Buspirone for opioid tapering  Number patients 
ceased/reduced. 
 
NCT03743402 Recruiting patients Strategies to improve pain and enjoy life (STRIPE) Dose reduction, 
pain. 
 





NCT03916276 Recruiting patients Living In Full Even (LIFE) with pain study Dose reduction, 
pain. 
 
NCT03950791 Recruiting patients Single session class to reduce opioid use in chronic pain Dose reduction, 
pain. 
 





NCT04097743 Not yet recruiting Pain catastrophizing and prescription opioid craving Dose reduction, 
pain 
 
ISRCTN49470934  Ongoing, no longer 
recruiting 
Improving the wellbeing of people living with opioid treated 





pain, QoL and AE. 
 
Table 1 Description of included studies. 
 
Abbreviations: USA = United States of America; SAE = Serious Adverse Event; AE = Adverse Event; QoL = Quality of Life; QD = quaque die (i.e. once daily); BID = bis in 
die (i.e. twice daily). 
